Every Form 4 that Pasithea Therapeutics Corp. (KTTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KTTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KTTA filings page.
Pasithea Therapeutics Corp. insider Coastlands Capital LP reported an open-market purchase of 100,000 shares of common stock at $0.53 per share. After this transaction, Coastlands Capital LP is shown as indirectly owning 3,835,035 common shares through its investment partnership structure.
The filing notes that Coastlands Capital LP, its related general partners and control person Matthew Perry are reporting jointly and each disclaims beneficial ownership of the common stock beyond any pecuniary interest. Coastlands Capital LP is identified as a more than ten percent owner of Pasithea Therapeutics.
Pasithea Therapeutics Corp. reported that Chief Executive Officer Tiago Marques received a stock option grant covering 1,756,069 shares of common stock. The option has an exercise price of $0.841 per share and expires on April 30, 2036.
According to the grant terms, 33% of the underlying shares vest on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years, as long as he remains in continuous service. All unvested shares fully vest upon a Change in Control under the company’s 2023 Stock Incentive Plan. Vested options may generally be exercised for up to three years after termination of continuous service, other than for cause.
Pasithea Therapeutics Corp. director Lawrence Steinman received a grant of stock options as part of equity compensation. The award covers 152,783 stock options for common stock with an exercise price of $0.841 per share and an expiration date in 2036.
These options vest in full on the one-year anniversary of the grant date if he remains a director through that date, and will fully vest earlier upon a Change in Control as defined in the company’s 2023 Stock Incentive Plan.
Pasithea Therapeutics Corp. director Simon Dumesnil received a grant of stock options covering 152,783 shares of common stock. The options have an exercise price of $0.841 per share and were awarded as compensation under the company’s 2023 Stock Incentive Plan.
The options vest in full on the one-year anniversary of the grant date if he remains a director, and will fully vest earlier upon a defined Change in Control. Following this grant, Dumesnil holds 152,783 derivative securities representing rights to acquire common shares, with the options scheduled to expire on April 30, 2036.
Pasithea Therapeutics Corp. reported that its Chief Financial Officer, Daniel H. Schneiderman, received a grant of stock options covering 1,129,323 shares of common stock. The options have an exercise price of $0.8410 per share and expire in 2036.
According to the company’s 2023 Stock Incentive Plan, 33% of the underlying shares vest on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years, assuming continuous service. The options fully vest upon a Change in Control as defined in the plan, and vested options may generally be exercised for up to three years after termination of continuous service other than for cause.
Pasithea Therapeutics Corp. granted Chief Medical Officer Kartik Krishnan a stock option to acquire 1,129,323 shares of common stock at an exercise price of $0.841 per share. This is a compensation-related award, not an open-market purchase or sale.
The option was granted under the company’s 2023 Stock Incentive Plan. 33% of the underlying shares vest on the one-year anniversary of the grant date, and the remaining shares vest in equal quarterly installments over the following two years, subject to continued service. All shares underlying the option fully vest upon a Change in Control as defined in the plan.
Vested and exercisable shares may be exercised for up to three years after termination of continuous service, except in the case of termination for Cause. Following this grant, Krishnan’s reported derivative holdings from this option total 1,129,323 option shares.
Pasithea Therapeutics Corp. director Emer Leahy received a stock option grant covering 152,783 shares of common stock. The option was awarded under the company’s 2023 Stock Incentive Plan with an exercise price of $0.841 per share and expires on April 30, 2036.
The underlying 152,783 shares will vest in full on the one-year anniversary of the grant date if Leahy remains a director through that date. The shares also fully vest upon a Change in Control as defined in the plan. After this grant, Leahy holds 152,783 options directly.
Pasithea Therapeutics Corp. director Alfred J. Novak received a grant of stock options covering 152,783 shares of common stock. The options have an exercise price of $0.8410 per share and were awarded under the company’s 2023 Stock Incentive Plan.
The options vest in full on the one-year anniversary of the grant date if Novak continues to serve as a director through that date. The award will also fully vest upon a Change in Control, as defined in the plan, providing additional equity-based compensation tied to his board service.
Pasithea Therapeutics Corp. (KTTA) director Lawarence Steinman reported a stock option grant. The Form 4 shows a stock option for 242,913 shares of common stock at an exercise price of $0.715, granted on 10/24/2025 and expiring on 10/23/2035. The option was awarded under the company’s 2023 Stock Incentive Plan.
The shares underlying the option vest in full on the one-year anniversary of the grant date, provided he remains a director through that date, and will fully vest upon a Change in Control as defined in the plan.
Pasithea Therapeutics (KTTA) disclosed a Form 4 showing CFO Daniel Schneiderman received a stock option for 317,266 shares at an exercise price of $0.715 per share on 10/24/2025, expiring 10/23/2035. The award vests 33% on the one-year anniversary of grant, with the balance vesting in equal quarterly installments over the next two years, subject to continuous service. The option fully vests upon a Change in Control as defined in the plan. Vested options may be exercised for up to three years after service ends, except in cases of termination for cause.
Pasithea Therapeutics (KTTA) reported a director stock option grant on a Form 4. The award is for 42,913 stock options at an exercise price of $0.715 per share, with a transaction date of 10/24/2025 and direct ownership.
The options vest in full on the one-year anniversary of the grant date, provided the individual remains a director through that date, and will fully vest upon a Change in Control as defined in the company’s 2023 Stock Incentive Plan. The options expire on 10/23/2035.
Pasithea Therapeutics (KTTA) disclosed that CEO and director Dr. Tiago Reis Marques was granted a stock option to purchase 493,341 shares of common stock at an exercise price of $0.715 per share. The grant date was 10/24/2025 and the option expires on 10/23/2035.
The option vests 33% on the one-year anniversary of grant, with the remainder vesting in equal quarterly installments over the following two years, subject to continued service. The option fully vests upon a Change in Control as defined in the company’s 2023 Stock Incentive Plan, and vested portions may be exercised for up to three years following termination of continuous service (except for cause).
Pasithea Therapeutics (KTTA) reported a director’s stock option award. On 10/24/2025, Dr. Emer Leahy acquired a stock option for 42,913 shares of common stock at an exercise price of $0.715 per share, expiring on 10/23/2035. The filing shows 42,913 derivative securities beneficially owned directly after the transaction. According to the company’s 2023 Stock Incentive Plan, the shares underlying the option vest in full on the one-year anniversary of the grant if the individual remains a director, and fully vest upon a Change in Control.
Pasithea Therapeutics (KTTA) filed a Form 4 reporting a director stock option grant. On 10/24/2025, the director received an option to purchase 42,913 shares of common stock at an exercise price of $0.715 per share under the company’s 2023 Stock Incentive Plan. The option expires on 10/23/2035 and will vest in full on the one-year anniversary of the grant date, provided the director remains on the board through that date; the award will fully vest upon a Change in Control as defined in the plan.